1. Clinical & Scientific Overview
Moxifloxacin & Ofloxacin (TIP-MED-000152, Reference Code [8.24]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisomerase IV Inhibitors (Schedule H1 [Moxifloxacin] / Schedule H [Ofloxacin] | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.24], p. 104): Moxifloxacin: Avelox (Bayer), Mahaflox (Mankind), Moxif (Torrent). Ofloxacin: Zanocin (Sun), Tarivid (Sanofi), Oflox (Cipla) — Strengths & Dosage Forms: Moxifloxacin Tablets: 400 mg; IV Infusion: 400 mg/250 mL. Ofloxacin Tablets: 200 mg, 400 mg; Syrup: 50 mg/5mL; IV: 200 mg/100 mL
Moxifloxacin Tablets: 400 mg; IV Infusion: 400 mg/250 mL. Ofloxacin Tablets: 200 mg, 400 mg; Syrup: 50 mg/5mL; IV: 200 mg/100 mL
3. Mechanism of Action & Pharmacodynamics
Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisomerase IV Inhibitors (Schedule H1 [Moxifloxacin] / Schedule H [Ofloxacin] | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisomerase IV Inhibitors (Schedule H1 [Moxifloxacin] / Schedule H [Ofloxacin] | NLEM 2022) for Moxifloxacin ('Respiratory & Anti-TB Fluoroquinolone'): Severe CAP, complicated intra-abdominal/skin infections, and drug-resistant Tuberculosis (BPaLM / MDR-TB). NOTE: Moxifloxacin has low urinary excretion (~20%) and MUST NOT be used for UTIs! Ofloxacin: Complicated UTI, prostatitis, enteric fever, PID, and leprosy.
4. Therapeutic Indications & Evidence-Supported Uses
- Moxifloxacin ('Respiratory & Anti-TB Fluoroquinolone'): Severe CAP, complicated intra-abdominal/skin infections, and drug-resistant Tuberculosis (BPaLM / MDR-TB)
- NOTE: Moxifloxacin has low urinary excretion (~20%) and MUST NOT be used for UTIs! Ofloxacin: Complicated UTI, prostatitis, enteric fever, PID, and leprosy
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Moxifloxacin: 400 mg PO or IV Once Daily (Fixed 400 mg OD dose across all renal stages!). Ofloxacin: 200–400 mg PO/IV BD (every 12 hours)
Administration & Meal Timing: May be taken with or without food; MUST separate by AT LEAST 4 HOURS from Calcium, Iron, Zinc, Magnesium, Aluminium Antacids, and Sucralfate! | Moxifloxacin: Once Daily (Morning). Ofloxacin: Morning & Evening (12-hourly BD)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Moxifloxacin is hepatically/biliary cleared -> NO renal dose adjustment required (400 mg OD in all CKD stages!). Ofloxacin is 85% renally cleared -> halve dose (200 mg OD) if CrCl 20–50 mL/min, and 100 mg OD if CrCl <20 mL/min! Hepatic: Avoid Moxifloxacin in Child–Pugh C cirrhosis
Renal: Moxifloxacin is hepatically/biliary cleared -> NO renal dose adjustment required (400 mg OD in all CKD stages!). Ofloxacin is 85% renally cleared -> halve dose (200 mg OD) if CrCl 20–50 mL/min, and 100 mg OD if CrCl <20 mL/min! Hepatic: Avoid Moxifloxacin in Child–Pugh C cirrhosis
Renal: Moxifloxacin is hepatically/biliary cleared -> NO renal dose adjustment required (400 mg OD in all CKD stages!). Ofloxacin is 85% renally cleared -> halve dose (200 mg OD) if CrCl 20–50 mL/min, and 100 mg OD if CrCl <20 mL/min! Hepatic: Avoid Moxifloxacin in Child–Pugh C cirrhosis
7. Contraindications, Precautions & High-Risk Warnings
- BOXED WARNINGS & SCHEDULE H1 DISTINCTION: Moxifloxacin is a Schedule H1 drug (requires 3-year Schedule H1 register entry!), whereas Ofloxacin is Schedule H. Boxed warnings for Tendinitis / Achilles Tendon Rupture, Peripheral Neuropathy, CNS Effects, Aortic Aneurysm, and Myasthenia Gravis! Moxifloxacin causes the greatest QTc prolongation among fluoroquinolones!
Key Clinical Precautions: Renal: Moxifloxacin is hepatically/biliary cleared -> NO renal dose adjustment required (400 mg OD in all CKD stages!). Ofloxacin is 85% renally cleared -> halve dose (200 mg OD) if CrCl 20–50 mL/min, and 100 mg OD if CrCl <20 mL/min! Hepatic: Avoid Moxifloxacin in Child–Pugh C cirrhosis
8. Adverse Effects Profile
- Nausea, diarrhoea, dizziness, headache, insomnia
- Torsades de Pointes (Moxifloxacin prolongs QTc by 6–15 ms — contraindicated with Class IA/III antiarrhythmics or hypokalaemia!), Achilles tendon rupture (especially >60 yr or on Corticosteroids!), dysglycaemia, hepatotoxicity (Moxifloxacin), C. difficile colitis
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CHELATION FAILURE: Antacids, Iron, Calcium, Zinc, and Sucralfate reduce absorption by 60%–90%! Additive QTc prolongation with Amiodarone, Sotalol, Ondansetron, Domperidone, Haloperidol, Escitalopram, and HCQ; Corticosteroids increase tendon rupture risk 15-fold; NSAIDs increase seizure risk; Warfarin INR elevation
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: THREE COUNTER RULES: (1) Space at least 4 hours away from Iron, Calcium, Zinc, or Antacids; (2) Stop immediately and rest the leg if any heel or Achilles tendon pain/swelling occurs; (3) Never use Moxifloxacin (Mahaflox) for a urine infection (it does not concentrate in urine!)
- Meal & Clock Timing Instruction: May be taken with or without food; MUST separate by AT LEAST 4 HOURS from Calcium, Iron, Zinc, Magnesium, Aluminium Antacids, and Sucralfate! (Moxifloxacin: Once Daily (Morning). Ofloxacin: Morning & Evening (12-hourly BD))
- Missed Dose Protocol: Take as soon as remembered unless within 6–8h of next dose
- Geriatric Dispensing Pearl: Avoid fluoroquinolones in older adults unless no safer alternative exists (high risk of tendon rupture, aortic dissection, delirium, and dysglycaemia)
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Moxifloxacin Tablets: 400 mg; IV Infusion: 400 mg/250 mL. Ofloxacin Tablets: 200 mg, 400 mg; Syrup: 50 mg/5mL; IV: 200 mg/100 mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.24] (p. 104)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.23]-C65 Gentamicin Sulfate — Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H
- [8.24]-C66 Ofloxacin — Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisom
- [8.25]-C67 Sulfamethoxazole (Co-trimoxazole 1:5 FDC) — Synergistic Sequential Folate Pathway Inhibitor — DHFR + DHPS Blo
- [8.27]-C68 Teicoplanin — Glycopeptide Cell-Wall D-Ala-D-Ala Peptidoglycan Inhibitors — ICM
